145 related articles for article (PubMed ID: 35721333)
1. Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis.
Choi S; Oh S; Yoon HS
Ann Dermatol; 2022 Jun; 34(3):173-181. PubMed ID: 35721333
[TBL] [Abstract][Full Text] [Related]
2. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
3. Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules.
He H; Wu W; Zhang Y; Zhang M; Sun N; Zhao L; Wang X
Front Pharmacol; 2021; 12():586827. PubMed ID: 34276352
[No Abstract] [Full Text] [Related]
4. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
5. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.
Hwang YJ; Youn SW; Kim BR; Yu DY; Kim Y; Pires A; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
J Dermatol; 2017 May; 44(5):560-566. PubMed ID: 27864841
[TBL] [Abstract][Full Text] [Related]
6. Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis.
Golhen K; Winskill C; Theiler M; Buettcher M; Yeh YH; Zhang N; Welzel T; Pfister M
Front Med (Lausanne); 2022; 9():944208. PubMed ID: 36226155
[TBL] [Abstract][Full Text] [Related]
7. Body Mass Index, Disease Duration and Tumor Necrosis Factor Inhibitor History Predict Reduced Ustekinumab Response in Chinese Psoriasis Patients: A Real-World Study.
Xu X; Qin G; Meng Z; Pei D
Indian J Dermatol; 2021; 66(5):574. PubMed ID: 35068529
[TBL] [Abstract][Full Text] [Related]
8. Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice.
Caldarola G; Mariani M; Pirro F; Nicolotti N; Burlando M; Calabrese L; Parodi A; Peris K; De Simone C
Expert Opin Biol Ther; 2021 Feb; 21(2):279-286. PubMed ID: 33170052
[No Abstract] [Full Text] [Related]
9. Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
Lockshin B; Harrison RW; McLean RR; Crabtree MM; Konicek BW; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Burge RT
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2797-2815. PubMed ID: 36331713
[TBL] [Abstract][Full Text] [Related]
10. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of ustekinumab for treatment of moderate to severe psoriasis: a prospective study in a clinical setting.
Molina-Leyva A; Husein-Elahmed H; Naranjo-Sintes R; Ruiz-Carrascosa JC
J Drugs Dermatol; 2014 Aug; 13(8):971-4. PubMed ID: 25116977
[TBL] [Abstract][Full Text] [Related]
12. PASI90 response: the new standard in therapeutic efficacy for psoriasis.
Puig L
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):645-8. PubMed ID: 25370811
[TBL] [Abstract][Full Text] [Related]
13. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
Vilarrasa E; Notario J; Bordas X; López-Ferrer A; Gich IJ; Puig L
J Am Acad Dermatol; 2016 Jun; 74(6):1066-72. PubMed ID: 27004803
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation.
Galluzzo M; Talamonti M; De Simone C; D'Adamio S; Moretta G; Tambone S; Caldarola G; Fargnoli MC; Peris K; Bianchi L
Expert Opin Biol Ther; 2018 Jul; 18(7):727-735. PubMed ID: 29798698
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of ustekinumab for moderate-to-severe psoriasis: A 9-year real-life experience from a tertiary referral center in Turkey.
Babuna Kobaner G; Polat Ekinci A; Kutlay A
Dermatol Ther; 2021 Jul; 34(4):e15042. PubMed ID: 34161621
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.
Umezawa Y; Torisu-Itakura H; Morisaki Y; ElMaraghy H; Nakajo K; Akashi N; Saeki H;
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):568-576. PubMed ID: 30325534
[TBL] [Abstract][Full Text] [Related]
17. Tobacco smoking negatively influences the achievement of greater than three-quarters reduction in psoriasis area and severity index after eight weeks of treatment among patients with psoriasis: Findings from a prospective study.
Qiang Y; Kuai L; Liu S; Xu Q; Shenfan L; Zhang R; Gao Z; Gao X; Li B; Wang R
Tob Induc Dis; 2024; 22():. PubMed ID: 38605857
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Pinter A; Costanzo A; Khattri S; Smith SD; Carrascosa JM; Tada Y; Riedl E; Reich A; Brnabic A; Haustrup N; Lampropoulou A; Lipkovich I; Kadziola Z; Paul C; Schuster C
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1479-1493. PubMed ID: 38113010
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab in psoriasis: Five-year real life experience from a single tertiary centre.
Acer E; İğrek A; Erdoğan HK; Saracoğlu ZN
Dermatol Ther; 2020 Mar; 33(2):e13224. PubMed ID: 31917491
[TBL] [Abstract][Full Text] [Related]
20. Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis.
Sun HY; Keller E; Suresh H; Sebaratnam DF
JAAD Int; 2021 Dec; 5():1-8. PubMed ID: 34816130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
